Vitamin Supplementation as an Adjuvant Treatment for Alzheimer's Disease
- PMID: 27656493
- PMCID: PMC5028542
- DOI: 10.7860/JCDR/2016/20273.8261
Vitamin Supplementation as an Adjuvant Treatment for Alzheimer's Disease
Abstract
Alzheimer's Disease (AD) is a slowly progressing neurodegenerative disorder representing a major health concern worldwide. This disorder is characterised by progressive dementia and cognitive decline. The pathological hallmarks of AD include the presence of Aβ plaques and tau neurofibrils. Research has shown that oxidative stress represents a major risk factor associated with AD pathology. Accumulation of Aβ plaques and relative lack of antioxidant defence mechanisms, including cellular antioxidant enzymes and dietary antioxidants like vitamins, assist in the exacerbation of oxidative stress. Reactive Oxygen Species (ROS) produced as the result of oxidative stress, that increase structural and functional abnormalities in brain neurons, which then manifests as dementia and decline in cognition. Data from numerous epidemiological studies suggests that nutrition is one of the most important yet modifiable risk factors for AD. Since oxidative stress contributes a great deal in the development and progression of AD, anything that could attenuate oxidative stress would help in decreasing the prevalence and incidence of AD. There is increasing evidence that supports the use of different antioxidant as an adjuvant treatment for AD. Vitamins are one such antioxidant that can be used as an adjuvant in AD treatment. This paper will focus on the evidence, based on current literature, linking the use of vitamin supplementations as an adjuvant treatment for AD.
Keywords: Antioxidant vitamins; Oxidative stress; Reactive oxygen species.
Similar articles
-
Role of Vitamin E in the Treatment of Alzheimer's Disease: Evidence from Animal Models.Int J Mol Sci. 2017 Nov 23;18(12):2504. doi: 10.3390/ijms18122504. Int J Mol Sci. 2017. PMID: 29168797 Free PMC article. Review.
-
Antioxidant pathways in Alzheimer's disease: possibilities of intervention.Curr Pharm Des. 2011 Dec;17(35):3861-4. doi: 10.2174/138161211798357755. Curr Pharm Des. 2011. PMID: 21933145 Review.
-
Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease.Ital J Biochem. 2003 Dec;52(4):177-81. Ital J Biochem. 2003. PMID: 15141484 Review.
-
The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer's Disease.Oxid Med Cell Longev. 2015;2015:352723. doi: 10.1155/2015/352723. Epub 2015 Jun 15. Oxid Med Cell Longev. 2015. PMID: 26171115 Free PMC article. Review.
-
Alzheimer's disease.Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.
Cited by
-
The Neuropathological Impacts of COVID-19: Challenges and Alternative Treatment Options for Alzheimer's Like Brain Changes on Severely SARS-CoV-2 Infected Patients.Am J Alzheimers Dis Other Demen. 2023 Jan-Dec;38:15333175231214974. doi: 10.1177/15333175231214974. Am J Alzheimers Dis Other Demen. 2023. PMID: 37972355 Free PMC article. Review.
-
Calcium handling: a strategy to fight neurodegeneration in Alzheimer's disease.Neural Regen Res. 2023 Dec;18(12):2685-2686. doi: 10.4103/1673-5374.374004. Neural Regen Res. 2023. PMID: 37449622 Free PMC article. No abstract available.
-
The Role of Dietary Antioxidants and Their Potential Mechanisms in Alzheimer's Disease Treatment.Metabolites. 2023 Mar 17;13(3):438. doi: 10.3390/metabo13030438. Metabolites. 2023. PMID: 36984879 Free PMC article. Review.
-
Integrated multi-omics analysis of Alzheimer's disease shows molecular signatures associated with disease progression and potential therapeutic targets.Sci Rep. 2023 Mar 6;13(1):3695. doi: 10.1038/s41598-023-30892-6. Sci Rep. 2023. PMID: 36879094 Free PMC article.
-
Upregulation of Ca2+-binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer's disease in Tg2576 mice.Mol Neurodegener. 2022 Nov 25;17(1):76. doi: 10.1186/s13024-022-00580-6. Mol Neurodegener. 2022. PMID: 36434727 Free PMC article.
References
-
- Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeits Psychiat Psychisch Gerichtlich Med. 1907;64:146–48.
-
- Alzheimer’s Association. 2012 Alzheimer’s disease facts and figures. Alzheimers Dement. 2012;8:131–68. - PubMed
-
- Lindsay J, Laurin D, Verreault R, Hébert R, Helliwell B, Hill GB, et al. Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian study of health and aging. Am J Epidemiol. 2002;156:445–53. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources